Literature DB >> 26762168

Characterization of a new low-dose 6-hydroxydopamine model of Parkinson's disease in rat.

Anna-Maija Penttinen1, Ilida Suleymanova1, Katrina Albert1, Jenni Anttila1, Merja H Voutilainen1, Mikko Airavaara1.   

Abstract

Intrastriatal administration of 6-hydroxydopamine (6-OHDA) induces partial degeneration of the nigrostriatal pathway, mimicking the pathology of Parkinson's disease (PD). Setting up the partial lesion model can be challenging because a number of experimental settings can be altered. This study compares seven experimental settings in a single study on d-amphetamine-induced rotations, tyrosine hydroxylase (TH)-positive neurites in the striatum, dopamine transporter (DAT)-positive neurites in the striatum, and TH-positive cells in the substantia nigra pars compacta (SNpc) in rats. Moreover, we validate a new algorithm for estimating the number of TH-positive cells. We show that the behavior and immunoreactivity vary greatly depending on the injection settings, and we categorize the lesions as progressive, stable, or regressive based on d-amphetamine-induced rotations. The rotation behavior correlated with the degree of the lesion, analyzed by immunohistochemistry; the largest lesions were in the progressive group, and the smallest lesions were in the regressive group. We establish a new low-dose partial 6-OHDA lesion model in which a total of 6 μg was distributed evenly to three sites in the striatum at a 10° angle. The administration of low-dose 6-OHDA produced stable and reliable rotation behavior and induced partial loss of striatal TH-positive and DAT-positive neurites and TH-positive cells in the SNpc. This model is highly suitable for neurorestoration studies in the search for new therapies for PD, and the new algorithm increases the efficacy for estimating the number of dopamine neurons. This study can be extremely useful for laboratories setting up the partial 6-OHDA model.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  6-OHDA; AB_2190413; AB_2201528; RGD_5508396; dopamine; dopamine transporter; nlx_153890; partial striatal lesion; striatum; substantia nigra; tyrosine hydroxylase

Mesh:

Substances:

Year:  2016        PMID: 26762168     DOI: 10.1002/jnr.23708

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  13 in total

1.  Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's disease.

Authors:  Andrea Herrera; Patricia Muñoz; Irmgard Paris; Gabriela Díaz-Veliz; Sergio Mora; Jose Inzunza; Kjell Hultenby; Cesar Cardenas; Fabián Jaña; Rita Raisman-Vozari; Katia Gysling; Jorge Abarca; Harry W M Steinbusch; Juan Segura-Aguilar
Journal:  Cell Mol Life Sci       Date:  2016-03-21       Impact factor: 9.261

2.  The Treadmill Exercise Protects against Dopaminergic Neuron Loss and Brain Oxidative Stress in Parkinsonian Rats.

Authors:  Roberta Oliveira da Costa; Carlos Vinicius Jataí Gadelha-Filho; Ayane Edwiges Moura da Costa; Mariana Lima Feitosa; Dayane Pessoa de Araújo; Jalles Dantas de Lucena; Pedro Everson Alexandre de Aquino; Francisco Arnaldo Viana Lima; Kelly Rose Tavares Neves; Glauce Socorro de Barros Viana
Journal:  Oxid Med Cell Longev       Date:  2017-06-21       Impact factor: 6.543

3.  Brief isoflurane anesthesia regulates striatal AKT-GSK3β signaling and ameliorates motor deficits in a rat model of early-stage Parkinson's disease.

Authors:  Juuso V Leikas; Samuel Kohtala; Wiebke Theilmann; Aaro J Jalkanen; Markus M Forsberg; Tomi Rantamäki
Journal:  J Neurochem       Date:  2017-06-14       Impact factor: 5.372

4.  Pre-α-pro-GDNF and Pre-β-pro-GDNF Isoforms Are Neuroprotective in the 6-hydroxydopamine Rat Model of Parkinson's Disease.

Authors:  Anna-Maija Penttinen; Ilmari Parkkinen; Merja H Voutilainen; Maryna Koskela; Susanne Bäck; Anna Their; Christopher T Richie; Andrii Domanskyi; Brandon K Harvey; Raimo K Tuominen; Liina Nevalaita; Mart Saarma; Mikko Airavaara
Journal:  Front Neurol       Date:  2018-06-20       Impact factor: 4.003

5.  A deep convolutional neural network approach for astrocyte detection.

Authors:  Ilida Suleymanova; Tamas Balassa; Sushil Tripathi; Csaba Molnar; Mart Saarma; Yulia Sidorova; Peter Horvath
Journal:  Sci Rep       Date:  2018-08-27       Impact factor: 4.379

6.  Sleep-State Dependent Alterations in Brain Functional Connectivity under Urethane Anesthesia in a Rat Model of Early-Stage Parkinson's Disease.

Authors:  Ekaterina Zhurakovskaya; Juuso Leikas; Tiina Pirttimäki; Francesc Casas Mon; Mikko Gynther; Rubin Aliev; Tomi Rantamäki; Heikki Tanila; Markus M Forsberg; Olli Gröhn; Jaakko Paasonen; Aaro J Jalkanen
Journal:  eNeuro       Date:  2019-02-26

7.  GDNF Receptor Agonist Alleviates Motor Imbalance in Unilateral 6-Hydroxydopamine Model of Parkinson's Disease.

Authors:  Yulia A Sidorova; Mart Saarma; Raimo K Tuominen; Juho-Matti Renko; Merja H Voutilainen; Tanel Visnapuu
Journal:  Front Neurol Neurosci Res       Date:  2020-11-24

Review 8.  Glial Cell Line-Derived Neurotrophic Factor Family Ligands, Players at the Interface of Neuroinflammation and Neuroprotection: Focus Onto the Glia.

Authors:  Anastasiia Kotliarova; Yulia A Sidorova
Journal:  Front Cell Neurosci       Date:  2021-06-17       Impact factor: 5.505

9.  Neuroprotection against 6-OHDA toxicity in PC12 cells and mice through the Nrf2 pathway by a sesquiterpenoid from Tussilago farfara.

Authors:  Joohee Lee; Kwangho Song; Eugene Huh; Myung Sook Oh; Yeong Shik Kim
Journal:  Redox Biol       Date:  2018-06-01       Impact factor: 11.799

10.  Implementation of deep neural networks to count dopamine neurons in substantia nigra.

Authors:  Anna-Maija Penttinen; Ilmari Parkkinen; Sami Blom; Jaakko Kopra; Jaan-Olle Andressoo; Kari Pitkänen; Merja H Voutilainen; Mart Saarma; Mikko Airavaara
Journal:  Eur J Neurosci       Date:  2018-09-20       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.